CHF Solutions, Inc. Announces 27% Revenue Growth for its Second Quarter and Provides Company Update

Eden Prairie, Minnesota, UNITED STATES

EDEN PRAIRIE, Minn., Aug. 07, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announced today its second quarter results for the period ended June 30, 2018.  Highlights include:

  • Revenue for second quarter ended June 30, 2018 increased 27 percent compared to the same period in 2017 and six percent sequentially over the first quarter of 2018.
  • Expanded US sales territories from ten to 13 and hired and trained three additional sales representatives.
  • In July 2018, received a blanket purchase agreement from the United States Department of Veteran’s Affairs for up to a maximum of $6.5 million to supply Aquadex FlexFlow systems for outpatient services. The blanket purchase agreement is for a period of up to five-years and allows but does not obligate the purchase of the products.
  • Recently published data at the International Society for Pharmaeconomics and Outcomes Research conference shows that hospitals that use an ultrafiltration system versus diuretic therapy save an average of $3,975 per patient at 90 days due to a reduction of patient readmission rates and duration of stay.
  • Continued international expansion and announced entrance into the German market by signing an agreement with HSC, our current European logistics provider.
  • Subsequent to quarter end, completed an underwritten public equity offering for net proceeds of approximately $4.7 million.

“We have continued to incrementally execute on our expansion strategy, including continued upward trends in our revenue,” said John Erb, Chairman and CEO. “We continue to be optimistic about our future growth and look forward to reporting further developments.”

The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.

To access the live webcast, please visit the Investors page of the CHF Solutions website at Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 8576075. An audio archive of the webcast will be available following the call on the Investor page at

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies.  The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statement regarding the benefits from using the Aquadex FlexFlow, trends in our revenue, our expansion plan and our future growth and developments.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our business strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited and in thousands, except per share amounts)

 Three months ended
June 30,
Six months ended
June 30,
  2018 2017    2018 2017
Net sales$1,099 $864 $2,136 $1,765 
Costs and expenses:            
  Cost of goods sold 870  616  1,771  1,130 
  Selling, general and administrative 3,765  2,420  7,776  4,807 
  Research and development 643  327  1,122  635 
  Total costs and expenses 5,278  3,363  10,669  6,572 
  Loss from operations (4,179) (2,499) (8,533) (4,807)
Other income (expense):            
  Other income, net -  5  -  11 
  Warrant valuation expense -  -  -  (67)
  Change in fair value of warrant liability -  37  -  1,466 
  Total other income, net -  42  -  1,410 
  Loss before income taxes (4,179) (2,457) (8,533) (3,397)
  Income tax benefit (expense), net (2) (1) (2) (1)
Net loss$(4,181)$(2,458)$(8,535)$(3,398)
Basic and diluted loss per share$(0.93)$(9.38)$(2.00)$(27.77)
Weighted average shares outstanding – basic and diluted 4,494  371  4,263  225 
Other comprehensive loss:            
  Foreign currency translation adjustments$(2)$(5)$(1)$(6)
Total comprehensive loss$(4,183)$(2,463)$(8,536)$(3,404)


Condensed Consolidated Balance Sheets  
(in thousands, except share and per share amounts)  
  June 30,
2018 (unaudited)
  December 31, 2017

Current assets       
  Cash and cash equivalents  $6,995 $15,595  
  Accounts receivable 652  545  
  Inventory 2,315  1,588  
  Other current assets 205  136  
Total current assets 10,167  17,864  
  Property, plant and equipment, net 576  570  
  Other assets 195  21  
TOTAL ASSETS$10,938 $18,455  
Current liabilities       
  Accounts payable and accrued expenses$838 $862  
  Accrued compensation 979  1,021  
  Other current liabilities 186  208  
Total current liabilities 2,003  2,091  
  Other liabilities 126  126  
Total liabilities 2,129  2,217  
Commitments and contingencies   —    —  
Stockholders’ equity       
Series A junior participating preferred stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 30,000 shares, none outstanding     
Series F convertible preferred stock as of June 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 610 and 3,780 shares, respectively, issued and outstanding 610 and 3,780, respectively     
Preferred stock as of June 30, 2018 and December 31, 2017, par value
$0.0001 per share; authorized 39,969,390 and 39,966,220 shares, none outstanding
   —    —  
Common stock as of June 30, 2018 and December 31, 2017, par value
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding
4,505,953 and 3,798,929, respectively
Additional paid‑in capital 198,474  197,367  
Accumulated other comprehensive income:       
  Foreign currency translation adjustment 1,226  1,227  
Accumulated deficit (190,891) (182,356) 
Total stockholders’ equity 8,809  16,238  


Condensed Consolidated Statements of Cash Flows 
(Unaudited, in thousands) 
  Six months ended
June 30,
  2018  2017  
Operating Activities:       
Net loss$(8,535)$(3,398)
Adjustments to reconcile net loss to cash flows used in operating activities:      
  Depreciation and amortization expense 115  436 
  Stock-based compensation expense, net 1,107  281 
  Change in fair value of warrant liability -  (1,466)
  Warrant valuation expense -  67 
Changes in operating assets and liabilities:      
  Accounts receivable (107) (336)
  Inventory (727) (187)
  Other current assets (48) 8 
  Accounts payable and accrued expenses (283) (1,103)
Net cash used in operations (8,478) (5,698)
Investing Activities:      
  Purchases of property and equipment (121) (20)
Net cash used in investing activities (121) (20)
Financing Activities:      
  Net proceeds from public stock offering -  8,002 
  Net proceeds from exercise of warrants -  1,768 
  Net proceeds from the sale of preferred stock and warrants -  184 
Net cash (used in) provided by financing activities -  9,954 
Effect of exchange rate changes on cash (1) (1)
Net (decrease) increase in cash and cash equivalents (8,600) 4,235 
Cash and cash equivalents - beginning of period 15,595  1,323 
Cash and cash equivalents - end of period$6,995 $5,558 
Supplement schedule of non-cash activities      
  Warrants issued as inducement to warrant exercise$- $509 
  Conversion of temporary equity to permanent equity$- $485 
  Financing fees included in long-term assets and accounts payable$195 $- 


Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.

Bret Shapiro
Managing Partner

Jules Abraham
JQA Partners, Inc.